Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free AHG Stock Alerts

Akso Health Group (AHG) Financials

Akso Health Group logo
$1.51 0.00 (0.00%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$1.52 +0.01 (+0.99%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Akso Health Group

Annual Income Statements for Akso Health Group

This table shows Akso Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 3.54 8.57 65 5.53 -71 -35 -17 -1.36 -9.46 -135 -19
Consolidated Net Income / (Loss)		 3.54 8.57 66 5.53 -71 -35 -17 -1.25 -9.52 -135 -19
Net Income / (Loss) Continuing Operations		 3.54 8.57 66 -7.62 -47 -4.29 -4.10 -13 -9.12 -135 -19
Total Pre-Tax Income 		4.17 10 77 -6.81 -47 -4.29 -4.01 -13 -9.09 -166 -21
Total Operating Income		 4.14 9.91 76 -7.19 -48 -4.24 -3.26 -14 -8.64 -166 -21
Total Gross Profit		 12 18 99 3.70 6.91 0.00 0.61 1.27 0.12 -0.28 -0.01
Total Revenue		 12 23 107 3.70 6.96 0.00 6.00 13 2.41 15 14
Operating Revenue		 12 23 107 3.70 6.96 0.00 6.00 13 2.41 15 14
Total Cost of Revenue		 0.00 5.15 8.50 0.00 0.04 0.00 5.39 12 2.29 15 14
Operating Cost of Revenue		 - 5.15 8.50 0.00 0.04 0.00 5.39 12 2.29 15 14
Total Operating Expenses		 7.75 7.86 23 11 55 2.09 3.06 16 8.76 166 21
Selling, General & Admin Expense		 1.55 2.65 5.82 3.13 20 2.03 2.67 16 8.59 3.64 3.99
Marketing Expense		 3.84 5.21 15 1.17 1.46 0.00 0.00 0.01 0.17 0.00 0.00
Impairment Charge		 - - - 0.00 29 - - 0.00 0.00 162 17
Total Other Income / (Expense), net		 0.03 0.18 1.32 0.38 1.23 -2.21 -1.55 1.20 -0.45 0.03 -0.00
Other Income / (Expense), net		 0.03 0.18 1.32 0.38 1.23 -0.05 -0.75 1.20 -0.45 0.03 -0.00
Income Tax Expense		 0.63 1.52 11 0.81 0.49 0.00 0.09 0.02 0.02 -31 -1.99
Net Income / (Loss) Discontinued Operations		 - - - 13 -24 -31 -13 12 -0.40 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 0.03 - 0.00 0.00 0.00 0.11 -0.06 -0.49 -0.04
Basic Earnings per Share		 $0.08 $0.20 $1.46 $0.11 ($1.46) ($0.71) ($0.28) ($0.02) $0.07 $0.16 $0.01
Weighted Average Basic Shares Outstanding		 42.08M 42.33M 44.98M 48.69M 48.76M 48.84M 59.61M 68.60M 141.52M 855.29M 2.17B
Diluted Earnings per Share		 $0.08 $0.20 $1.37 $0.10 ($1.46) ($0.71) ($0.28) ($0.02) $0.07 $0.16 $0.01
Weighted Average Diluted Shares Outstanding		 42.08M 42.33M 47.66M 52.91M 48.76M 48.84M 59.61M 68.60M 141.52M 855.29M 2.17B
Weighted Average Basic & Diluted Shares Outstanding		 - - 47.96M 49.20M 48.82M 48.85M 68.60M 68.60M 437.17M 1.66B 2.57B

Quarterly Income Statements for Akso Health Group

No quarterly income statements for Akso Health Group are available.

Annual Cash Flow Statements for Akso Health Group

This table details how cash moves in and out of Akso Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 6.86 11 113 -75 25 4.20 6.80 -13 77 90 -176
Net Cash From Operating Activities		 7.03 8.19 88 -1.73 -58 10 -8.63 -3.25 1.35 1.18 -13
Net Cash From Continuing Operating Activities		 7.03 8.19 88 1.12 -35 -7.60 -11 -5.98 0.71 1.18 -13
Net Income / (Loss) Continuing Operations		 3.54 8.57 66 -7.62 -47 -4.29 -4.10 -13 -9.12 -135 -19
Depreciation Expense		 0.06 0.09 0.17 0.02 0.12 - - 0.00 0.00 2.15 2.37
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.00 1.83 7.67 41 -3.11 0.39 8.27 7.77 162 17
Changes in Operating Assets and Liabilities, net		 3.43 -0.47 20 1.05 -29 -0.20 -7.57 -1.17 2.06 -28 -13
Net Cash From Discontinued Operating Activities		 - - - -2.85 -23 18 2.65 2.73 0.65 0.00 0.00
Net Cash From Investing Activities		 -0.12 -0.29 -28 -68 13 -0.00 -20 18 -55 -106 -163
Net Cash From Continuing Investing Activities		 -0.12 -0.29 -28 -67 17 0.00 -20 18 -55 -106 -163
Purchase of Property, Plant & Equipment		 -0.12 -0.29 -0.46 -0.01 -0.20 - - 0.00 0.00 -0.15 -0.00
Acquisitions		 - - - - - - - 0.00 -56 -94 -176
Other Investing Activities, net		 0.00 0.00 -27 -51 32 0.00 -20 18 1.53 -12 12
Net Cash From Discontinued Investing Activities		 - - - -1.00 -4.60 -0.00 0.04 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.24 4.29 48 -0.03 -1.55 -9.04 35 -28 132 196 0.35
Net Cash From Continuing Financing Activities		 0.24 4.29 48 51 -8.21 4.63 9.10 -28 132 196 0.35
Repayment of Debt		 -10 2.29 4.35 51 0.00 4.63 -0.91 -28 -7.69 0.00 0.00
Issuance of Debt		 - 0.00 0.00 20 -6.65 - - - - 0.00 0.35
Issuance of Common Equity		 0.00 2.00 48 - 0.00 0.00 10 0.00 139 196 0.00
Net Cash From Discontinued Financing Activities		 - - - -51 6.65 -14 26 0.00 0.00 0.00 0.00
Other Net Changes in Cash		 - - - - 0.61 3.18 - - - -1.12 -0.15
Cash Interest Paid		 - - - 0.00 2.41 - 0.68 0.34 0.11 0.00 0.00
Cash Income Taxes Paid		 0.00 0.30 1.02 12 3.21 2.11 0.09 0.02 0.02 0.00 0.00

Quarterly Cash Flow Statements for Akso Health Group

No quarterly cash flow statements for Akso Health Group are available.

Annual Balance Sheets for Akso Health Group

This table presents Akso Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 28 164 173 80 32 63 20 142 215 190
Total Current Assets		 23 163 98 52 30 63 20 142 196 190
Cash & Equivalents		 19 133 57 6.67 15 18 7.92 85 176 0.17
Accounts Receivable		 - 0.00 0.42 24 8.90 20 9.23 0.00 13 1.28
Inventories, net		 - - - - 0.00 7.80 1.69 0.19 0.19 0.20
Prepaid Expenses		 4.14 1.25 3.33 0.43 0.60 0.18 0.27 57 6.81 12
Other Current Assets		 0.00 - - - - - - - 0.00 176
Plant, Property, & Equipment, net		 0.43 0.77 1.25 0.09 0.07 0.00 0.00 0.00 0.02 0.01
Total Noncurrent Assets		 4.58 0.00 74 28 1.50 0.00 0.00 0.00 19 0.08
Goodwill		 - - - - - - - 0.00 11 0.00
Intangible Assets		 - - - - - - - 0.00 7.88 0.06
Other Noncurrent Operating Assets		 4.18 - 0.00 0.67 - - - 0.00 0.10 0.02
Total Liabilities & Shareholders' Equity		 28 164 173 80 32 63 20 142 215 190
Total Liabilities		 4.88 24 47 32 14 51 12 3.59 16 8.71
Total Current Liabilities		 0.79 24 27 12 14 51 12 3.59 14 8.71
Accounts Payable		 0.79 - - 3.24 4.11 0.23 0.94 1.10 1.52 1.83
Current Deferred & Payable Income Tax Liabilities		 - 20 9.37 - 0.30 0.09 0.10 0.07 0.03 0.09
Other Current Liabilities		 - 0.00 14 0.74 - 37 9.69 2.00 12 6.78
Total Noncurrent Liabilities		 4.09 0.00 20 20 0.00 0.00 0.00 0.00 1.99 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - 0.00 1.95 0.00
Other Noncurrent Operating Liabilities		 4.09 0.00 0.00 0.01 - - - 0.00 0.04 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 24 140 127 48 17 12 8.84 138 199 181
Total Preferred & Common Equity		 24 140 127 48 17 12 8.73 138 199 181
Total Common Equity		 24 140 127 48 17 12 8.73 138 199 181
Common Stock		 13 58 60 61 61 71 71 210 406 406
Retained Earnings		 12 77 70 -1.43 -36 -53 -54 -64 -199 -218
Treasury Stock		 - 0.00 -1.32 -3.99 -3.99 -3.99 -3.99 -3.99 -3.99 -3.99
Accumulated Other Comprehensive Income / (Loss)		 -1.54 4.38 -1.76 -7.05 -3.10 -1.65 -3.85 -4.09 -3.77 -3.28
Noncontrolling Interest		 - - - - 0.00 0.00 0.11 0.06 0.03 -0.01

Quarterly Balance Sheets for Akso Health Group

No quarterly balance sheets for Akso Health Group are available.

Annual Metrics And Ratios for Akso Health Group

This table displays calculated financial ratios and metrics derived from Akso Health Group's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 47,958,550.00 49,204,083.00 48,818,340.00 48,850,574.00 68,598,050.00 68,598,050.00 - 437,170,960.00 2,570,112,530.00
DEI Adjusted Shares Outstanding		 0.00 0.00 15,986,183.00 16,401,361.00 16,272,780.00 48,850,574.00 68,598,050.00 68,598,050.00 - 437,170,960.00 2,570,112,530.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 4.10 0.34 -4.38 -0.71 -0.25 -0.02 - -0.31 -0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 92.70% 367.96% -96.55% 88.33% -100.00% 0.00% 119.69% -81.68% 512.08% -6.40%
EBITDA Growth		 0.00% 140.90% 659.64% -108.78% -588.48% 90.82% 6.64% -225.99% 30.42% -1,705.15% 88.83%
EBIT Growth		 0.00% 142.23% 664.85% -108.82% -588.50% 90.84% 6.64% -225.99% 30.42% -1,728.80% 87.55%
NOPAT Growth		 0.00% 139.42% 671.46% -107.75% -569.14% 91.18% 23.12% -337.57% 39.45% -1,825.26% 87.55%
Net Income Growth		 0.00% 142.22% 664.34% -91.55% -1,386.89% 51.08% 51.62% 92.60% -662.90% -1,323.51% 86.18%
EPS Growth		 0.00% 150.00% 585.00% -91.55% -1,386.89% 51.37% 60.56% 92.86% -250.00% -128.57% -93.75%
Operating Cash Flow Growth		 0.00% 16.57% 971.13% -101.97% -3,266.62% 117.26% -185.78% 62.29% 141.53% -12.88% -1,186.62%
Free Cash Flow Firm Growth		 0.00% 0.00% 1,390.39% -190.54% 44.39% 230.71% -52.28% -202.04% -198.09% -45.84% -100.18%
Invested Capital Growth		 0.00% 0.00% 73.70% 686.21% -4.39% -78.23% -178.61% 102.82% 19,682.44% -56.96% 688.58%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 77.53% 92.08% 100.00% 99.35% 0.00% 10.09% 9.63% 5.06% -1.91% -0.08%
EBITDA Margin		 35.55% 44.44% 72.14% -183.77% -671.80% 0.00% -66.80% -99.13% -376.57% -1,110.59% -132.54%
Operating Margin		 34.81% 43.25% 70.74% -194.55% -691.24% 0.00% -54.34% -108.23% -357.78% -1,125.37% -149.66%
EBIT Margin		 35.03% 44.04% 71.97% -184.24% -673.53% 0.00% -66.80% -99.13% -376.57% -1,125.14% -149.69%
Profit (Net Income) Margin		 29.75% 37.39% 61.08% 149.72% -1,023.06% 0.00% -280.83% -9.46% -394.17% -916.71% -135.31%
Tax Burden Percent		 84.92% 84.92% 85.59% -81.27% 151.89% 811.19% 420.37% 9.55% 104.67% 81.48% 90.40%
Interest Burden Percent		 100.00% 100.00% 99.14% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 15.08% 15.08% 14.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 394.11% 1,110.86% -15.31% -59.01% 0.00% -175.77% 0.00% -22.60% -305.66% -14.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 392.53% 1,110.12% -25.83% 65.07% 0.00% -67.71% 0.00% -15.19% -291.08% -9.44%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -321.18% -1,030.75% 19.46% -22.54% 0.00% 61.76% 0.00% 9.67% 225.40% 4.38%
Return on Equity (ROE)		 0.00% 72.93% 80.11% 4.15% -81.55% -106.55% -114.01% -11.81% -12.92% -80.26% -9.85%
Cash Return on Invested Capital (CROIC)		 0.00% 194.11% 1,057.01% -170.17% -54.53% 119.75% 0.00% -7,356.40% -220.58% -226.03% -169.21%
Operating Return on Assets (OROA)		 0.00% 35.56% 80.30% -4.04% -36.95% 0.00% -8.48% -31.38% -11.19% -93.16% -10.23%
Return on Assets (ROA)		 0.00% 30.20% 68.14% 3.28% -56.12% 0.00% -35.66% -3.00% -11.71% -75.90% -9.25%
Return on Common Equity (ROCE)		 0.00% 72.93% 80.11% 4.15% -81.55% -106.55% -114.01% -11.74% -12.91% -80.24% -9.85%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 36.47% 46.78% 4.37% -148.02% -201.64% -137.17% 0.00% -6.88% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.52 8.42 65 -5.03 -34 -2.97 -2.28 -9.99 -6.05 -116 -14
NOPAT Margin		 29.56% 36.73% 60.55% -136.19% -483.87% 0.00% -38.04% -75.76% -250.45% -787.76% -104.76%
Net Nonoperating Expense Percent (NNEP)		 0.00% 1.59% 0.75% 10.52% -124.08% 2,497.27% -108.07% 57.49% -7.40% -14.58% -4.79%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -112.98% - -58.45% -8.01%
Cost of Revenue to Revenue		 0.00% 22.47% 7.92% 0.00% 0.65% 0.00% 89.91% 90.37% 94.94% 101.91% 100.08%
SG&A Expenses to Revenue		 13.07% 11.54% 5.42% 84.75% 294.41% 0.00% 44.50% 117.81% 355.86% 24.64% 28.84%
R&D to Revenue		 19.83% 0.00% 0.00% 0.00% 14.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 65.19% 34.28% 21.34% 294.55% 790.59% 0.00% 51.02% 117.86% 362.84% 1,123.46% 149.57%
Earnings before Interest and Taxes (EBIT)		 4.17 10 77 -6.81 -47 -4.29 -4.01 -13 -9.09 -166 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4.23 10 77 -6.79 -47 -4.29 -4.01 -13 -9.09 -164 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.42 0.14 0.55 2.24 0.93 0.19 0.86 1.84
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.42 0.14 0.55 2.24 0.93 0.19 0.95 1.84
Price to Revenue (P/Rev)		 0.00 0.00 0.00 14.45 0.99 0.00 4.59 0.62 10.99 11.64 24.02
Price to Earnings (P/E)		 0.00 0.00 0.00 9.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 3.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 10.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.33 0.36 0.00 1.14 0.00 0.00 1.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 2.68 0.00 1.52 0.02 0.00 0.00 24.01
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.11 0.47 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.16 0.42 0.58 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.16 0.42 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.82 -0.93 -0.75 -0.35 0.04 -0.91 -1.44 -0.64 -0.77 -0.46
Leverage Ratio		 0.00 1.21 1.18 1.26 1.45 1.72 3.20 3.94 1.10 1.06 1.06
Compound Leverage Factor		 0.00 1.21 1.17 1.26 1.45 1.72 3.20 3.94 1.10 1.06 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 13.65% 29.37% 36.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 36.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 13.65% 29.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 1.29% 0.04% 0.02% -0.01%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 86.35% 70.63% 63.33% 99.98% 98.71% 99.96% 99.98% 100.01%
Debt to EBITDA		 0.00 0.00 0.00 -2.95 -0.43 -2.33 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 10.04 -0.25 1.19 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -2.95 -0.43 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -3.97 -0.59 -3.37 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 13.54 -0.35 1.73 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -3.97 -0.59 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 1.63 -1.14 -1.06 -0.74 -4.25 4.77 3.77 22.14
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.55% 0.12% 0.03% 0.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 29.62 6.84 3.68 4.21 2.09 1.24 1.76 39.52 14.20 21.77
Quick Ratio		 0.00 24.37 6.79 3.55 3.47 2.05 0.76 1.48 23.70 13.69 0.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 4.15 62 -56 -31 41 19 -20 -59 -86 -172
Operating Cash Flow to CapEx		 5,832.13% 2,845.98% 19,236.24% -102,491.12% -30,267.59% 0.00% 0.00% 0.00% 0.00% 762.12% -780,909.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 18.88 24.13 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.67 -10.73 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.67 -10.73 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.81 1.12 0.02 0.05 0.00 0.13 0.32 0.03 0.08 0.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.58 0.00 0.42 0.90 0.00 0.00 1.95
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.51 2.44 78.96 70.92
Fixed Asset Turnover		 0.00 53.56 179.51 3.66 10.34 0.00 0.00 0.00 0.00 0.00 982.27
Accounts Payable Turnover		 0.00 6.53 0.00 0.00 0.00 0.00 2.49 20.46 2.24 11.47 8.25
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 630.15 0.00 879.08 404.64 0.00 0.00 187.05
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 145.27 149.49 4.62 5.15
Days Payable Outstanding (DPO)		 0.00 55.94 0.00 0.00 0.00 0.00 146.72 17.84 162.70 31.83 44.25
Cash Conversion Cycle (CCC)		 0.00 -55.94 0.00 0.00 630.15 0.00 732.36 532.06 -13.21 -27.21 147.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 4.27 7.42 58 56 12 -9.55 0.27 53 23 181
Invested Capital Turnover		 0.00 10.73 18.35 0.11 0.12 0.00 4.62 -2.84 0.09 0.39 0.14
Increase / (Decrease) in Invested Capital		 0.00 4.27 3.15 51 -2.56 -44 -22 9.82 53 -30 158
Enterprise Value (EV)		 0.00 0.00 0.00 -15 19 4.42 9.09 0.31 -59 -4.24 332
Market Capitalization		 0.00 0.00 0.00 53 6.89 9.55 28 8.12 27 172 332
Book Value per Share		 $0.00 $0.56 $3.11 $2.64 $0.98 $0.35 $0.25 $0.13 $2.02 $0.46 $0.08
Tangible Book Value per Share		 $0.00 $0.56 $3.11 $2.64 $0.98 $0.35 $0.25 $0.13 $2.02 $0.41 $0.08
Total Capital		 0.00 24 140 147 68 27 12 8.84 138 199 181
Total Debt		 0.00 0.00 0.00 20 20 10 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 20 20 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -19 -133 -68 12 -5.13 -18 -7.92 -85 -176 -0.17
Capital Expenditures (CapEx)		 0.12 0.29 0.46 0.00 0.19 0.00 0.00 0.00 0.00 0.15 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 3.35 6.65 14 33 11 -6.14 0.92 53 6.08 181
Debt-free Net Working Capital (DFNWC)		 0.00 23 139 71 40 26 12 8.84 138 182 181
Net Working Capital (NWC)		 0.00 23 139 71 40 16 12 8.84 138 182 181
Net Nonoperating Expense (NNE)		 -0.02 -0.15 -0.57 -11 38 32 15 -8.74 3.47 19 4.23
Net Nonoperating Obligations (NNO)		 0.00 -19 -133 -68 7.68 -5.13 -22 -8.57 -85 -176 -0.17
Total Depreciation and Amortization (D&A)		 0.06 0.09 0.17 0.02 0.12 0.00 0.00 0.00 0.00 2.15 2.37
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 14.62% 6.20% 371.99% 474.01% 0.00% -102.41% 6.94% 2,205.58% 41.16% 1,306.16%
Debt-free Net Working Capital to Revenue		 0.00% 98.53% 129.85% 1,924.59% 569.83% 0.00% 204.76% 67.06% 5,733.42% 1,233.69% 1,307.40%
Net Working Capital to Revenue		 0.00% 98.53% 129.85% 1,924.59% 569.83% 0.00% 204.76% 67.06% 5,733.42% 1,233.69% 1,307.40%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $4.38 $0.33 ($4.38) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16) $0.01
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 14.99M 16.23M 16.25M 48.84M 59.61M 68.60M 141.52M 855.29M 2.17B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $4.11 $0.30 ($4.38) ($0.71) ($0.28) ($0.02) ($0.07) ($0.16) $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 15.89M 17.64M 16.25M 48.84M 59.61M 68.60M 141.52M 855.29M 2.17B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 15.99M 16.40M 16.27M 48.85M 68.60M 68.60M 437.17M 1.66B 2.57B
Normalized Net Operating Profit after Tax (NOPAT)		 3.52 8.42 65 -5.03 -13 -2.93 -2.01 -9.99 -6.05 -2.75 -2.80
Normalized NOPAT Margin		 29.56% 36.73% 60.55% -136.19% -190.26% 0.00% -33.47% -75.76% -250.45% -18.58% -20.24%
Pre Tax Income Margin		 35.03% 44.04% 71.36% -184.24% -673.53% 0.00% -66.80% -99.13% -376.57% -1,125.14% -149.69%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.99 -4.98 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.38 -2.84 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.99 -4.98 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -1.38 -2.84 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 7.04% 353.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 7.04% 382.93% -3.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Akso Health Group

No quarterly metrics and ratios for Akso Health Group are available.


Financials Breakdown Chart

Akso Health Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Akso Health Group's fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Akso Health Group's net income appears to be on an upward trend, with a most recent value of -$18.72 million in 2026, falling from $3.54 million in 2016. The previous period was -$135.47 million in 2025. Find out what analysts predict for Akso Health Group in the coming months.

Akso Health Group's total operating income in 2026 was -$20.70 million, based on the following breakdown:
  • Total Gross Profit: -$11.32 thousand
  • Total Operating Expenses: $20.69 million

Over the last 10 years, Akso Health Group's total revenue changed from $11.89 million in 2016 to $13.83 million in 2026, a change of 16.3%.

Akso Health Group's total liabilities were at $8.71 million at the end of 2026, a 44.9% decrease from 2025, and a 78.6% increase since 2017.

In the past 9 years, Akso Health Group's cash and equivalents has ranged from $170.57 thousand in 2026 to $176.23 million in 2025, and is currently $170.57 thousand as of their latest financial filing in 2026.

Over the last 10 years, Akso Health Group's book value per share changed from 0.00 in 2016 to 0.08 in 2026, a change of 8.4%.


Related Companies

Financial statements for NASDAQ:AHG last updated on 7/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel